Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Elon Musk said his xAI's Grok-3 model could help someone complete a flawless March Madness bracket and win Warren Buffett's ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...

AMD remains a strong buy with a $170 target price, thanks to its strong position in AI market, market share gains and ...

A judge in California has ruled that a law banning so-called pay-to-delay deals between pharma companies cannot be enforced ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...